slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 72,301-72,330
Pages 3,679
Rows per page 30
Component
72,301-72,330 of 110,355
22
The slide uses a circular process diagram to show the feedback loop of immune cell activation and hair follicle damage.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
23
Includes photographic evidence of hair regrowth over 21 days and a bar chart showing fold reduction of NKG2D marker.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
24
The slide compares two different drugs (baricitinib and deuruxolitinib) using their respective clinical trial data (BRAVE AA1 and THRIVE AA1).Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
25
Includes a blackbox warning text block as a competitive/safety barrier context.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
26
The slide outlines a clinical trial methodology and the strategic positioning of the drug candidate.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
28
Uses a contrast-based framing (750k patients vs 0 drugs) to establish market opportunity.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
29
The slide uses a four-column structure to explain the biological rationale, molecular nature, mechanism of action, and clinical status.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
31
The slide uses a circular process diagram to show the mechanism of action and a bar chart to show efficacy.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
32
The slide uses a process-like flow to highlight the specific mechanism of action (IL-15/IL-21) compared to other approaches.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Why Now1 hit
33
The slide outlines a sequential clinical trial process.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Why Now1 hit
37
Includes a disclaimer regarding the Form 10-Q and a footnote about debt facility prepayment.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
38
The slide uses a table-like structure to present clinical trial milestones and financial runway.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
03
The slide uses a hub-and-spoke diagram to connect the company name to three core pillars: leadership, portfolio, and financials.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
09
The slide uses a matrix structure to map indications to benchmarks, specific drug regimens, and trial names, with a footer detailing active clinical trial collaboration and supply agreements (CTCSAs).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
10
The chart uses a stacked bar approach to represent US and European patient counts per clinical program.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
12
The kinome tree visualization (KINOMEscan) is a standard industry tool for demonstrating kinase selectivity.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
13
The slide combines a biological pathway diagram (mechanism of action) with a clinical trial summary table.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
16
Waterfall plot uses standard clinical trial terminology (PD, SD, PR). Comparison table highlights the study drug's performance against Dacarbazine and Binimetinib.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
17
The slide uses a before-and-after visual comparison to demonstrate clinical efficacy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
19
The slide highlights consistent clinical activity across two study phases, culminating in a combined ORR of 33.3%.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
20
Swimmer plot visualization of clinical trial data.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
21
The diagram uses a tree structure to categorize patient outcomes (off treatment vs on treatment, further broken down by SD and PR).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
28
Data shows tumor volume over time for various treatment groups including monotherapy and combinations.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
30
Data cut 23MAR2023. Table shows frequency of specific adverse events by severity grade and dosage cohort.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
31
The slide uses a process-oriented flow to demonstrate clinical validation milestones.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
32
The slide uses arrows to visually indicate performance superiority of ERAS-601 over RMC-4550.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
34
Includes RECIST 1.1 criteria reference and specific tumor measurements over time.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
35
The table displays counts and percentages of patients experiencing specific adverse events, categorized by severity (All vs Grade >= 3).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
37
The slide uses a stacked bar chart to show mutation incidence and a comparison table to highlight clinical trial failures in GBM despite success in other indications.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
38
The slide uses Western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit